The Medical Letter - 2010
Search or Select Article Below and Click to Purchase
Year:    Publication:      2010 Annual Index: U.S. English | Canadian English
January 11, 2010 (Issue 1329)  
January 25, 2010 (Issue 1330)  
  • Medical Marijuana
    Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will...
  • Glucose Control in the ICU
    Once thought to be a beneficial response to critical illness, hyperglycemia is now recognized as independently associated with death and other adverse outcomes in various groups of critically ill...
  • Ustekinumab (Stelara) for Psoriasis
    The FDA has approved the use of ustekinumab (Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe...
February 8, 2010 (Issue 1331)  
February 22, 2010 (Issue 1332)  
  • Iloperidone (Fanapt) - Another Second-Generation Antipsychotic
    The FDA has approved the marketing of iloperidone (Fanapt – Vanda), a second-generation antipsychotic, for treatment of schizophrenia. Iloperidone is chemically related to risperidone...
  • Vigabatrin (Sabril) for Epilepsy
    The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs...
March 8, 2010 (Issue 1333)  
  • Rosiglitazone (Avandia) Revisited
    The cardiovascular safety of the thiazolidinedione rosiglitazone (Avandia – GlaxoSmithKline) is in the news again, with some authorities calling for its removal from the market (New York...
  • Primary Prevention of Ulcers in Patients Taking Aspirin or NSAIDs
    Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have...
  • Hyperbaric Oxygen Therapy for Refractory Wounds
    Hyperbaric oxygen (HBO2) therapy, breathing 100% O2 while exposed to increased atmospheric pressure, has been used for years to treat refractory wounds, especially diabetic...
  • Addendum: Cost of Ustekinumab (Stelara)
    In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7), footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.
March 22, 2010 (Issue 1334)  
April 5, 2010 (Issue 1335)  
  • Liraglutide (Victoza) for Type 2 Diabetes
    Liraglutide (Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection, has been approved by the FDA for treatment of patients with type 2...
  • Plerixafor (Mozobil)
    The FDA has approved plerixafor (Mozobil – Genzyme), a CXCR4 chemokine receptor antagonist, for use in combination with granulocyte-colony stimulating factor (G-CSF; Neupogen) to...
April 19, 2010 (Issue 1336)  
May 3, 2010 (Issue 1337)  
May 17, 2010 (Issue 1338)  
  • Cervarix - A Second HPV Vaccine
    The FDA has approved a recombinant human papillomavirus (HPV) vaccine (Cervarix – GlaxoSmithKline) for use in girls and women 10-25 years old to prevent infection with HPV types 16 and 18,...
  • Which TNF Inhibitor for Rheumatoid Arthritis?
    The FDA has approved five tumor necrosis factor (TNF) inhibitors for treatment of moderately to severely active rheumatoid arthritis (RA). TNF-α is a pro-inflammatory cytokine involved in the...
  • Another Once-Daily Formulation of Tramadol (Ryzolt)
    The FDA has approved tramadol hydrochloride extended-release (Ryzolt – Purdue) for treatment of moderate to moderately severe chronic pain in adults. Tramadol is already available in...
May 31, 2010 (Issue 1339)  
June 14, 2010 (Issue 1340)  
June 28, 2010 (Issue 1341)  
  • In Brief: Only The Name Remains The Same
    A Medical Letter subscriber was surprised to discover that a new Citracal product contained not only calcium citrate, but also calcium carbonate. Citracal Plus Bone Density Builder...
  • Preservation of Ovarian Function During Chemotherapy
    Chemotherapy can result in premature menopause and infertility in young women. Pretreatment fertility counseling followed by appropriate action may prevent some of these undesirable consequences.
  • A Sumatriptan Needle-Free Injector for Migraine
    Sumatriptan was first marketed in the US in 1993 as Imitrex for subcutaneous injection, followed by tablets for oral administration and then by a nasal spray. It is one of seven serotonin...
  • Ofatumumab (Arzerra) for CLL
    The FDA has approved ofatumumab (Arzerra – GlaxoSmithKline), a human anti-CD20 monoclonal antibody, for treatment of patients with chronic lymphocytic leukemia (CLL) refractory to...
July 12, 2010 (Issue 1342)  
July 26, 2010 (Issue 1343)  
  • Pitavastatin (Livalo) - The Seventh Statin
    The FDA has approved the marketing of pitavastatin (Livalo – Kowa), an HMG-CoA reductase inhibitor (“statin”), for treatment of primary hyperlipidemia or mixed dyslipidemia. It has...
  • A New Conjugate Meningococcal Vaccine (Menveo)
    The FDA has approved Menveo (Novartis), a new quadrivalent conjugated polysaccharide vaccine, for protection against disease caused by Neisseria meningitidis in people 11-55 years old.
August 9, 2010 (Issue 1344)  
August 23, 2010 (Issue 1345)  
September 6, 2010 (Issue 1346)  
  • In Brief: Propoxyphene Toxicity
    The FDA has required manufacturers of propoxyphene-containing products (Darvon, and others) to strengthen boxed warnings to include the potential for overdose.1 This action followed...
  • New Treatments for Metastatic Prostate Cancer
    The FDA has approved 2 new treatments for castration-resistant (formerly called hormone-refractory) prostate cancer. Sipuleucel-T (Provenge – Dendreon) is the first immunotherapy approved...
  • Tribenzor for Hypertension
    Many patients with hypertension require more than one drug to control their blood pressure. Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment of hypertension, combines...
  • Natazia - A New Oral Contraceptive
    The FDA has approved the marketing of Natazia (Bayer), a 4-phase oral contraceptive containing the estrogen estradiol valerate and the progestin dienogest, both used for the first time in...
September 20, 2010 (Issue 1347)  
  • Dalfampridine (Ampyra) for MS
    The FDA has approved the use of dalfampridine (4-aminopyridine; Ampyra – Acorda), a potassium channel blocker, to improve walking speed in patients with multiple sclerosis (MS). Walking...
  • Naproxen/Esomeprazole (Vimovo)
    The FDA has approved the marketing of Vimovo (AstraZeneca), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) naproxen and the proton pump inhibitor (PPI)...
  • Nonstandard Uses of Chelation Therapy
    Chelation therapy involves oral administration, intravenous infusion or intramuscular injection of drugs that increase excretion of heavy metals. The Medical Letter’s last article on this...
October 4, 2010 (Issue 1348)  
October 18, 2010 (Issue 1349)  
November 1, 2010 (Issue 1350)  
  • Desirudin (Iprivask) for DVT Prevention
    The injectable direct thrombin inhibitor desirudin (Iprivask – Canyon), a recombinant analog of hirudin, the leech anticoagulant protein, was approved by the FDA in 2003 for prevention of...
  • Interferon Beta-1b (Extavia) for Multiple Sclerosis
    The FDA has approved a new interferon beta-1b product (Extavia – Novartis) for treatment of relapsing forms of multiple sclerosis (MS). Extavia is identical to Betaseron...
  • Rifaximin (Xifaxan 550) for Hepatic Encephalopathy
    The FDA has approved a new 550-mg tablet of rifaximin (Xifaxan – Salix), a minimally absorbed oral antibiotic, to reduce the risk of recurrent hepatic encephalopathy (HE). A 200-mg tablet...
  • In Brief: Sibutramine (Meridia) Withdrawn
    The results of a postmarketing study of its cardiovascular safety have led to the removal of the weightloss drug sibutramine (Meridia) from the market in the US and Canada. It has also been...
  • In Brief: Safety of Quinine
    Qualaquin, the only formulation of quinine sulfate available in the US, is approved only for treatment of uncomplicated malaria, but most prescriptions for its use are written for treatment...
November 15, 2010 (Issue 1351)  
November 29, 2010 (Issue 1352)  
  • In Brief: Clopidogrel and Omeprazole
    Use of a proton pump inhibitor (PPI) to protect against gastrointestinal (GI) bleeding in patients taking the antiplatelet agent clopidogrel (Plavix) may interfere with the activation of...
  • Drugs for Kidney Stones
    Renal colic is a common problem in emergency departments. Stones <5 mm in diameter often pass spontaneously; stones >10 mm in diameter generally do not. The usual treatment for stones that do...
  • Aliskiren/Amlodipine (Tekamlo): Another Combination Tablet for Hypertension
    The FDA has approved Tekamlo (Novartis), an oral fixed-dose combination of the direct renin inhibitor aliskiren (Tekturna) and the calcium channel blocker amlodipine...
  • Miconazole (Oravig) for Oropharyngeal Candidiasis
    The FDA has approved a buccal tablet formulation of miconazole (Oravig – Strativa) for local treatment of oropharyngeal candidiasis in adults. Miconazole has been available for many...
December 13, 2010 (Issue 1353)  
  • Bromocriptine (Cycloset) for Type 2 Diabetes
    The FDA has approved a new tablet formulation of bromocriptine mesylate (Cycloset – VeroScience) for treatment of type 2 diabetes in adults. Bromocriptine (Parlodel, and others)...
  • Oral Fingolimod (Gilenya) for Multiple Sclerosis
    The FDA has approved the marketing of fingolimod (Gilenya – Novartis) to reduce the frequency of clinical exacerbations and delay the accumulation of physical disability in patients with...
  • Drugs for Female Sexual Dysfunction
    Sexual complaints related to desire, arousal, orgasm and painful intercourse are common in women. Since the last Medical Letter article on this subject, some new information has become available.
  • Clindamycin-Tretinoin (Veltin Gel) for Acne
    Veltin Gel (Stiefel), a fixed-dose combination of the antibiotic clindamycin phosphate 1.2% and the retinoid tretinoin 0.025%, has been approved by the FDA for topical treatment of acne...
  • In Brief: An Oral Contraceptive with Folate
    Six years after an FDA advisory committee recommended development of a combination tablet containing an oral contraceptive and folic acid,1 the FDA has approved Beyaz (Bayer), a combination...
  • 2010 Annual Index (Online Only)
    View the 2010 Annual Index